



02-14-02

RECEIPT \$
Box Sec

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Robert Schlegel, *et al.*

Serial No.: 09/785,276

Filed: February 16, 2001

For: *NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF HUMAN PROSTATE CANCER*

Attorney Docket No.: MRI-007B

Group Art Unit: 1646

Examiner: Not yet assigned


Box Missing Parts
Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTION OF FILING RECEIPT

Dear Sir:


The Filing Receipt for the above-identified patent application incorrectly lists the filing date as "February 6, 2001" instead of "**February 16, 2001**".

Applicants request that the Filing Receipt be corrected and reissued. *A copy of the Filing Receipt with the changes noted thereon is submitted herewith.*

Certificate of First Class Mailing (37 CFR 1.8(a))	
I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231 on:	
February 6, 2002	_____
Date	_____
	_____
DeAnn F. Smith	Reg. No. 36,683

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



DeAnn F. Smith
Registration No. 36,683
Attorney for Applicants



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/785,276	02/06/2001 02/16/01	1646	2898	MRI-007B		66	20

CONFIRMATION NO. 3373

 000959
 LAHIVE & COCKFIELD
 28 STATE STREET
 BOSTON, MA 02109

FILING RECEIPT



OC000000007179455

Date Mailed: 12/11/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Robert Schlegel, Auburndale, MA;
 Wilson O. Endege, Norwood, MA;
 John E. Monahan, Walpole, MA;

Domestic Priority data as claimed by applicant

 THIS APPLN CLAIMS BENEFIT OF 60/183,319 02/17/2000
 AND CLAIMS BENEFIT OF 60/189,862 03/16/2000
 AND CLAIMS BENEFIT OF 60/207,454 05/25/2000
 AND CLAIMS BENEFIT OF 60/211,314 06/09/2000
 AND CLAIMS BENEFIT OF 60/219,007 07/18/2000
 AND CLAIMS BENEFIT OF 60/255,281 12/13/2000

Foreign Applications

If Required, Foreign Filing License Granted 12/10/2001


Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Novel genes, compositions, kits, and methods for identification, assessment, prevention, and



therapy of human prostate cancer

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).